{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:06:00Z","timestamp":1784009160923,"version":"3.55.0"},"reference-count":21,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Philadelphia chromosome-positive (Ph+) mixed-phenotype acute leukemia (MPAL) is a rare entity of acute leukemia. The co-occurrence of Ph+ MPAL and active Epstein\u2013Barr virus (EBV) viremia in a renal transplantation recipient represents an exceptionally rare and clinically challenging scenario. Here, we report a case of Ph+ MPAL arising concurrently with EBV infection in a patient who had undergone kidney transplantation nine years earlier. A tailored therapeutic strategy was implemented, combining olverembatinib with dexamethasone, lisaftoclax and azacitidine for leukemia treatment, alongside B-cell\u2013depleting therapy with rituximab for EBV viremia. This integrated approach successfully induced hematologic remission and achieved clearance of EBV viremia, providing a potential therapeutic framework for managing this complex dual condition. To our knowledge, this is the first reported case of this specific clinical triad, highlighting the significant therapeutic challenges posed by the coexistence of these conditions.<\/jats:p>","DOI":"10.3389\/fonc.2026.1865977","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:39:30Z","timestamp":1784007570000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A unique case of Philadelphia chromosome-positive mixed-phenotype acute leukemia with active Epstein-Barr virus infection in a kidney transplantation recipient"],"prefix":"10.3389","volume":"16","author":[{"given":"Mengping","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Hematology, Shaoxing People\u2019s Hospital","place":["Shaoxing, China"]},{"name":"Department of Hematology, the First Affiliated Hospital, Shaoxing University","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuelian","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiying","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shaoxing People\u2019s Hospital","place":["Shaoxing, China"]},{"name":"Department of Hematology, the First Affiliated Hospital, Shaoxing University","place":["Shaoxing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.202","article-title":"Mixed-phenotype acute leukemia: historical overview and a new definition","volume":"24","author":"Weinberg","year":"2010","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.path.2019.03.008","article-title":"Acute leukemias of ambiguous lineage: clarification on lineage specificity","volume":"12","author":"Kurzer","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25873","article-title":"Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome","volume":"95","author":"Qasrawi","year":"2020","journal-title":"Am J Hematol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.03.012","article-title":"Survival of patients with mixed phenotype acute leukemias: a large population-based study","volume":"39","author":"Shi","year":"2015","journal-title":"Leuk Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.955603","article-title":"Strategies of Epstein-Barr virus to evade innate antiviral immunity of its human host","volume":"13","author":"Albanese","year":"2022","journal-title":"Front Microbiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00901-20","article-title":"Association between antibody responses to Epstein-Barr virus glycoproteins, neutralization of infectivity, and the risk of nasopharyngeal carcinoma","volume":"5","author":"Zhu","year":"2020","journal-title":"mSphere"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2023.2196366","article-title":"Who is the patient at risk for EBV reactivation and disease: expert opinion focused on post-transplant lymphoproliferative disorders following hematopoietic stem cell transplantation","volume":"23","author":"Marjanska","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.19746\/j.cnki.issn1009-2137.2022.05.001","article-title":"Immunophenotypic features and clinical prognosis of patients with mixed phenotype acute leukemia","volume":"30","author":"Liu","year":"2022","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0058-4","article-title":"Therapy for children and adults with mixed phenotype acute leukemia: a systematic review and meta-analysis","volume":"32","author":"Maruffi","year":"2018","journal-title":"Leukemia"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.cll.2021.03.016","article-title":"Update on acute leukemias of ambiguous lineage","volume":"41","author":"Aggarwal","year":"2021","journal-title":"Clin Lab Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/MOH.0000000000000570","article-title":"Optimal therapeutic strategies for mixed phenotype acute leukemia","volume":"27","author":"Wolach","year":"2020","journal-title":"Curr Opin Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000554","article-title":"How to think about acute leukemia of ambiguous lineage","volume":"2024","author":"Weinberg","year":"2024","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"B13","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1111\/ejh.12343","article-title":"Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era","volume":"93","author":"Shimizu","year":"2014","journal-title":"Eur J Haematol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01680-9","article-title":"Olverembatinib: first approval","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1021\/jm301581y","article-title":"Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region-Abelson (Bcr-Abl) kinase and overcomes clinically acquired mutation-induced resistance against imatinib","volume":"56","author":"Ren","year":"2013","journal-title":"J Med Chem"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1546371","article-title":"Olverembatinib (HQP1351)-based therapy in adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia in blast phase: results from a real-world study","volume":"16","author":"Wen","year":"2025","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41375-025-02696-2","article-title":"Correction: Olverembatinib combined with venetoclax and reduced-intensity chemotherapy for adult newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a single-center, single-arm, phase 2 trial","volume":"39","author":"Gong","year":"2025","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-21-4037","article-title":"Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic Malignancy","volume":"28","author":"Deng","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-22-3321","article-title":"Novel BCL-2 inhibitor Lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic Malignancies: first-in-human open-label trial","volume":"29","author":"Ailawadhi","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2025.102216","article-title":"Forty years of kidney transplantation: insights into Malignancies at a single center in Latin America","volume":"90","author":"Musalem","year":"2025","journal-title":"Transpl Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2021.11.004","article-title":"The diagnostic value of whole blood Epstein-Barr virus DNA load in lymphoproliferative diseases after allogeneic hematopoietic stem cell transplantation","volume":"42","author":"Niu","year":"2021","journal-title":"Zhonghua Xue Ye Xue Za Zhi"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1865977\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T05:39:34Z","timestamp":1784007574000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1865977\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":21,"alternative-id":["10.3389\/fonc.2026.1865977"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1865977","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"article-number":"1865977"}}